BioInvent International (STO:BINV) - "This is an important next step for BioInvent," said Martin Welschof, Chief Executive Officer of BioInvent. "We are sharpening our clinical focus on our most advanced assets with the greatest potential impact and multiple upcoming catalysts, thus maintaining a strong foundation for future growth. Our decision reflects a disciplined, opportunity-driven approach that we believe will maximize both patient impact and shareholder value." - Martin Welschof, CEO of BioInvent.
EVENTS IN THE SECOND QUARTER
(R) Promising Phase 2a monotherapy data for BI-1808 in CTCL presented at EHA 2025
Promising Phase 1 data of BI-1206 in combination with KEYTRUDA® (pembrolizumab) in solid tumors announced
Poster highlighting model-informed early clinical development of anti-TNFR2 drug candidate BI-1910 presented at PAGE 2025
(R) XOMA Royalty purchases mezagitamab royalty and milestone rights held by BioInvent for up to USD 30 million
(R) Updated Phase 2a Triple Combination Arm Data of BI-1206, rituximab, and Calquence for the treatment of non-Hodgkin's lymphoma announced
FDA Fast Track Designation received for BI-1808 for the treatment of cutaneous T-cell lymphoma
BioInvent received milestone payment as Takeda moved mezagitamab into Phase 3
EVENTS AFTER THE END OF THE PERIOD
Strategic changes in portfolio to accelerate lead clinical programs and enhance value creation
Transgene and BioInvent to present updated data on armed oncolytic virus BT-001 at ESMO 2025
(R)= Regulatory event
FINANCIAL INFORMATION
Second quarter 2025
Net sales SEK 198.1 (4.6) million.
Profit/loss after tax SEK 38.8 (-137.3) million.
Profit/loss after tax per share before and after dilution SEK 0.59 (-2.09).
Cash flow from operating activities SEK 66.8 (-119.2) million.
Liquid funds, current and long-term investments at the end of the period SEK 797.5 (1,090.3) million.
The complete interim report is available for download below and on the company's website under Financial reports.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
This information is information that BioInvent International is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-08-26 08:30 CEST.
Attachments
BioInvent Q2, 2025 EN (25 Augusti)
SOURCE: BioInvent International
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvent-international-ab-interim-report-january-june-2025-1065376
